ResultsIQ

ResultsIQ › Latest results › Mankind Pharma Limited

Mankind Pharma Limited Q1 FY27 results deck summary

NSE: MANKIND · BSE: 543904

Results deck of 30 Jul 2026, summarised by AI from the filing.

Mankind Pharma Q1 FY27 revenue ₹4,031 cr (+12.9% YoY) with EBITDA margin 26.3% (+250 bps) and PAT ₹574 cr (+29.1%).

Key takeaways

  1. Guidance No forward guidance was provided in the presentation.
  2. Change Exports business grew 29.0% YoY to ₹605 cr, while Consumer Healthcare grew 3.9% YoY to ₹246 cr.
  3. Risk Consumer Healthcare growth was partly impacted by base effect of discontinued cash and carry business.

Original filing on BSE

Mankind Pharma Limited Q1 FY27 results

As filed: Revenue ₹4,031 cr (+13% year on year), EBITDA ₹1,056 cr (+25% year on year), PAT ₹574 cr (+29% year on year), EBITDA margin 26.2% (+248 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹3,443 cr (+12% year on year), EBITDA ₹930 cr (+36% year on year), PAT ₹559 cr (+32% year on year), EBITDA margin 27.0% (+479 bps). Score 63 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was well above it; profit growth was above it. EBITDA margin rose 479 bps year on year. Revenue fell 3% from last quarter. Revenue rose ₹364 cr on a year ago, against ₹638 cr the year before. Share price after the results: −3.5% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹3,567 cr (+10% year on year), EBITDA ₹919 cr (+11% year on year), PAT ₹414 cr (+24% year on year), EBITDA margin 25.8% (+8 bps). Score 42 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit before exceptional items growth was above it. EBITDA margin was flat year on year. Revenue fell 4% from last quarter. Revenue rose ₹337 cr on a year ago, against ₹623 cr the year before. Share price after the results: +3.0% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹3,697 cr (+20% year on year), EBITDA ₹922 cr (+8% year on year), PAT ₹520 cr (−21% year on year), EBITDA margin 24.9% (−272 bps). Score 44 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin fell 272 bps year on year. Revenue rose ₹620 cr on a year ago, more than the ₹369 cr it added the year before. Share price after the results: −4.5% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹3,570 cr (+23% year on year), EBITDA ₹847 cr (+24% year on year), PAT ₹445 cr (−18% year on year), EBITDA margin 23.7% (+15 bps). Score 56 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin rose 15 bps year on year. Revenue rose ₹677 cr on a year ago, more than the ₹314 cr it added the year before. Share price after the results: −3.7% in 29 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹3,079 cr (+26% year on year), EBITDA ₹684 cr (+16% year on year), PAT ₹425 cr (−11% year on year), EBITDA margin 22.2% (−200 bps). Score 40 of 100, Below trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 200 bps year on year. Other income 49% of PBT. Revenue fell 5% from last quarter. Share price after the results: −9.6% in 30 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹3,230 cr (+24% year on year), EBITDA ₹830 cr (+37% year on year), PAT ₹385 cr (−16% year on year), EBITDA margin 25.7% (+241 bps). Score 64 of 100, In line with trend. EBITDA margin rose 241 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 42% from last quarter.
  • Q2 FY25: Revenue ₹3,077 cr (+14% year on year), EBITDA ₹851 cr (+25% year on year), PAT ₹659 cr (+29% year on year), EBITDA margin 27.7% (+244 bps). Score 69 of 100, Above trend. EBITDA margin rose 244 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Mankind Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.